中科院《国际期刊预警名单(试行)》名单
2023年01月发布的2023版:不在预警名单中
2021年12月发布的2021版:不在预警名单中
2021年01月发布的2020版:不在预警名单中
《国际期刊预警名单(试行)》2023版共计包含28本期刊(查看)
《国际期刊预警名单(试行)》2021版共计包含35本期刊(查看)
《国际期刊预警名单(试行)》2020版共计包含65本期刊(查看)
《CLINICA CHIMICA ACTA》相关链接
PubMed Central (PMC)链接:
http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1873-3492%5BISSN%5D
平均审稿速度:
平均3.0个月来源Elsevier官网:平均5.2周
平均录用比例:
约50%
123学术网预审服务:
经过123学术网预审的论文,能够提前知晓自己的论文稿件是否达到自己目标分区、分值的杂志社的录用标准,同时节约自己大量投稿时间,若预审通过,123学术网客服会进一步向您反馈预审结果,如果双方对预审结果达成一致,则需要与我方签订咨询服务协议,以协助您结合审稿人的审稿意见进一步优化稿件质量,以实现文章录用结果。
若预审不能通过,说明论文稿件质量无法达到杂志社的录用标准,可考虑123学术网润色服务,不仅能满足CLINICA CHIMICA ACTA的语言要求,还能让CLINICA CHIMICA ACTA编辑和审稿人得到更好的审稿体验,让稿件最大限度被CLINICA CHIMICA ACTA编辑和审稿人充分理解和公正评估。
123学术网已助力全球10万+作者顺利发表论文。
《CLINICA CHIMICA ACTA》期刊简介
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal's scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.